Chizuko Koseki serves as CEO of TAGCyx Biotechnologies, a Japanese biotech firm specializing in drug-discovery platforms. She joined the organization as a consultant in 2015 and recognized an opportunity to pivot the company's focus from anti-counterfeiting applications toward pharmaceutical development. Her scientific background as a Ph.D. pharmacology researcher, combined with business experience gained in London's startup ecosystem, enabled her to lead that strategic transformation and secure substantial venture funding.
Since becoming president in 2017, Koseki has guided TAGCyx toward developing therapeutic candidates for conditions including alopecia areata, interstitial cystitis, and autoimmune disorders through the company's proprietary Xenoligo platform. Her ambitions extend beyond Japan, with plans to establish operations in London and Boston. She describes her move from academia into entrepreneurship as deeply rewarding, driven by seeing scientific breakthroughs translate into real benefits for patients.
